{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:26:13Z","timestamp":1787613973854,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20mk0101182h0001"],"award-info":[{"award-number":["JP20mk0101182h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23mk0121270h0001"],"award-info":[{"award-number":["JP23mk0121270h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xphs.2024.08.009","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T11:12:37Z","timestamp":1723720357000},"page":"3255-3264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Three-dimensional culture of human proximal tubular epithelial cells for an in vitro evaluation of drug-induced kidney injury"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-7646","authenticated-orcid":false,"given":"Hiroshi","family":"Arakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Nedachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeno","family":"Kadoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Morimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Jimbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-083X","authenticated-orcid":false,"given":"Ikumi","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2024.08.009_bib0001","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.153","article-title":"Raising awareness of acute kidney injury: a global perspective of a silent killer","volume":"84","author":"Lewington","year":"2013","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xphs.2024.08.009_bib0002","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1523-1755.2004.00927.x","article-title":"Spectrum of acute renal failure in the intensive care unit: the PICARD experience","volume":"66","author":"Mehta","year":"2004","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.xphs.2024.08.009_bib0003","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xphs.2024.08.009_bib0004","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.taap.2017.09.006","article-title":"Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: the IQ consortium nonclinical to clinical translational database","volume":"334","author":"Monticello","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"10.1016\/j.xphs.2024.08.009_bib0005","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1021\/mp400720w","article-title":"Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models","volume":"11","author":"Tiong","year":"2014","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2024.08.009_bib0006","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1124\/dmd.116.072066","article-title":"Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics","volume":"44","author":"Prasad","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.xphs.2024.08.009_bib0007","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.xphs.2024.08.009_bib0008","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","article-title":"Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions","volume":"176","author":"Ciarimboli","year":"2010","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.xphs.2024.08.009_bib0009","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/labinvest.2011.48","article-title":"Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters","volume":"91","author":"Kohler","year":"2011","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.xphs.2024.08.009_bib0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ki.1994.6","article-title":"HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney","volume":"45","author":"Ryan","year":"1994","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.xphs.2024.08.009_bib0011","doi-asserted-by":"crossref","first-page":"F1365","DOI":"10.1152\/ajprenal.90405.2008","article-title":"hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics","volume":"295","author":"Wieser","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.xphs.2024.08.009_bib0012","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00424-012-1163-2","article-title":"The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule","volume":"464","author":"Jenkinson","year":"2012","journal-title":"Pflugers Arch"},{"issue":"7","key":"10.1016\/j.xphs.2024.08.009_bib0013","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00204-019-02469-8","article-title":"Functional transepithelial transport measurements to detect nephrotoxicity in vitro using the RPTEC\/TERT1 cell line","volume":"93","author":"Secker","year":"2019","journal-title":"Arch Toxicol"},{"issue":"9","key":"10.1016\/j.xphs.2024.08.009_bib0014","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1124\/dmd.122.001171","article-title":"Improvement of protein expression profile in three-dimensional renal proximal tubular epithelial cell spheroids selected based on OAT1 gene expression: a potential in vitro tool for evaluating human renal proximal tubular toxicity and drug disposition","volume":"51","author":"Ishiguro","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.xphs.2024.08.009_bib0015","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s11095-006-9196-x","article-title":"Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2)","volume":"24","author":"Uwai","year":"2007","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2024.08.009_bib0016","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1208\/s12248-016-9871-8","article-title":"A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity","volume":"18","author":"Nieskens","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2024.08.009_bib0017","doi-asserted-by":"crossref","first-page":"e00090","DOI":"10.7554\/eLife.00090","article-title":"Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1","volume":"1","author":"Denard","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.xphs.2024.08.009_bib0018","first-page":"S70","article-title":"Cyclosporine-induced renal dysfunction in experimental animals and humans","volume":"52","author":"Remuzzi","year":"1995","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"10.1016\/j.xphs.2024.08.009_bib0019","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/ndt\/gfh967","article-title":"Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells","volume":"20","author":"McMorrow","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.xphs.2024.08.009_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11255-016-1439-0","article-title":"Klotho mitigates cyclosporine A (CsA)-induced epithelial-mesenchymal transition (EMT) and renal fibrosis in rats","volume":"49","author":"Liu","year":"2017","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"10.1016\/j.xphs.2024.08.009_bib0021","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/acs.chemrestox.8b00246","article-title":"Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs","volume":"32","author":"Rana","year":"2019","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10.1016\/j.xphs.2024.08.009_bib0022","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1681\/ASN.2015010060","article-title":"A quantitative approach to screen for nephrotoxic compounds in vitro","volume":"27","author":"Adler","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xphs.2024.08.009_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2020.152535","article-title":"Freshly isolated primary human proximal tubule cells as an in vitro model for the detection of renal tubular toxicity","volume":"442","author":"Bajaj","year":"2020","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.xphs.2024.08.009_bib0024","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0090-9556(24)15217-8","article-title":"Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes","volume":"27","author":"Granvil","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2024.08.009_bib0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1006\/taap.1994.1241","article-title":"Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney","volume":"129","author":"Zamlauski-Tucker","year":"1994","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2024.08.009_bib0026","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/bit.24707","article-title":"Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip","volume":"110","author":"Choucha-Snouber","year":"2013","journal-title":"Biotechnol Bioeng"},{"issue":"2","key":"10.1016\/j.xphs.2024.08.009_bib0027","doi-asserted-by":"crossref","first-page":"124","DOI":"10.31768\/2312-8852.2017.39(2):124-130","article-title":"Determination of cisplatin in human blood plasma and urine using liquid chromatography-mass spectrometry for oncological patients with a variety of fatty tissue mass for prediction of toxicity","volume":"39","author":"Gerina-Berzina","year":"2017","journal-title":"Exp Oncol"},{"issue":"6","key":"10.1016\/j.xphs.2024.08.009_bib0028","first-page":"891","article-title":"Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients","volume":"3","author":"Gamelin","year":"1997","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924003125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924003125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:57:50Z","timestamp":1777388270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924003125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0022354924003125"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.08.009","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-dimensional culture of human proximal tubular epithelial cells for an in vitro evaluation of drug-induced kidney injury","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}